Literature DB >> 21508649

Non-steroidal anti-inflammatory drug use and the risk of Parkinson's disease.

Angelika D Manthripragada1, Eva S Schernhammer, Jiaheng Qiu, Soren Friis, Lene Wermuth, Jorgen H Olsen, Beate Ritz.   

Abstract

BACKGROUND: Experimental evidence supports a preventative role for non-steroidal anti-inflammatory drugs (NSAIDs) in Parkinson's disease (PD).
METHODS: We investigated associations between use of aspirin, nonaspirin NSAIDs, and acetaminophen and PD in a large population-based case-control study using Danish health and pharmacy registries. We identified 1,931 PD cases reported in hospital or outpatient clinic records who had received a primary diagnosis of PD between 2001 and 2006, and 9,651 age- and sex-matched controls from the Danish population register. Prescription medication use was documented in a pharmacy database covering all residents of Denmark since 1995.
RESULTS: Adjusting for age, sex, use of cardiovascular disease drugs, diagnosis of chronic pulmonary obstructive disorder, and Charlson comorbidity scores, and excluding prescriptions filled within 5 years before diagnosis, we found no evidence for an association between PD and either aspirin use (OR = 0.97; 95% CI 0.82, 1.14) or nonaspirin NSAID use (OR = 0.97; 95% CI 0.86, 1.09), regardless of intensity of use; further, there was no association between use of ibuprofen or acetaminophen and PD.
CONCLUSION: Our findings provide no evidence for a protective effect of nonaspirin and aspirin NSAID prescription drug use shortly before PD onset.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21508649      PMCID: PMC3095838          DOI: 10.1159/000325653

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


  20 in total

Review 1.  Neuroprotective effects of nonsteroidal anti-inflammatory drugs on neurodegenerative diseases.

Authors:  M Asanuma; I Miyazaki; N Ogawa
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

2.  Risk for Parkinson's disease among patients with osteoarthritis: a Danish cohort study.

Authors:  Kathrine Rugbjerg; Søren Friis; Thomas L Jørgensen; Beate Ritz; Lise Korbo; Jørgen H Olsen
Journal:  Mov Disord       Date:  2010-10-30       Impact factor: 10.338

3.  Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.

Authors:  P K Morrish; J S Rakshi; D L Bailey; G V Sawle; D J Brooks
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-03       Impact factor: 10.154

4.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

5.  Ibuprofen protects dopaminergic neurons against glutamate toxicity in vitro.

Authors:  D Casper; U Yaparpalvi; N Rempel; P Werner
Journal:  Neurosci Lett       Date:  2000-08-11       Impact factor: 3.046

6.  Upper gastrointestinal bleeding among users of NSAIDs: a population-based cohort study in Denmark.

Authors:  Lene Mellemkjaer; William J Blot; Henrik Toft Sørensen; Lars Thomassen; Joseph K McLaughlin; Gunnar Lauge Nielsen; Jørgen H Olsen
Journal:  Br J Clin Pharmacol       Date:  2002-02       Impact factor: 4.335

Review 7.  Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis.

Authors:  Joshua J Gagne; Melinda C Power
Journal:  Neurology       Date:  2010-03-23       Impact factor: 9.910

Review 8.  Pathogenic role of glial cells in Parkinson's disease.

Authors:  Peter Teismann; Kim Tieu; Oren Cohen; Dong-Kug Choi; Du Chu Wu; Daniel Marks; Miquel Vila; Vernice Jackson-Lewis; Serge Przedborski
Journal:  Mov Disord       Date:  2003-02       Impact factor: 10.338

Review 9.  Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration?

Authors:  E C Hirsch; S Hunot; P Damier; B Faucheux
Journal:  Ann Neurol       Date:  1998-09       Impact factor: 10.422

10.  Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice.

Authors:  N Aubin; O Curet; A Deffois; C Carter
Journal:  J Neurochem       Date:  1998-10       Impact factor: 5.372

View more
  19 in total

Review 1.  Peripheral inflammation in neurodegeneration.

Authors:  Ulrike Träger; Sarah J Tabrizi
Journal:  J Mol Med (Berl)       Date:  2013-04-02       Impact factor: 4.599

Review 2.  Ageing, neurodegeneration and brain rejuvenation.

Authors:  Tony Wyss-Coray
Journal:  Nature       Date:  2016-11-10       Impact factor: 49.962

Review 3.  Pathways towards an effective immunotherapy for Parkinson's disease.

Authors:  Jessica A L Hutter-Saunders; Rodney Lee Mosley; Howard E Gendelman
Journal:  Expert Rev Neurother       Date:  2011-12       Impact factor: 4.618

Review 4.  Lessons learned from protein aggregation: toward technological and biomedical applications.

Authors:  César L Avila; Silvina Chaves; Sergio B Socias; Esteban Vera-Pingitore; Florencia González-Lizárraga; Cecilia Vera; Diego Ploper; Rosana Chehín
Journal:  Biophys Rev       Date:  2017-09-13

5.  PACAP deficiency sensitizes nigrostriatal dopaminergic neurons to paraquat-induced damage and modulates central and peripheral inflammatory activation in mice.

Authors:  M B Watson; H Nobuta; C Abad; S K Lee; N Bala; C Zhu; F Richter; M-F Chesselet; J A Waschek
Journal:  Neuroscience       Date:  2013-03-14       Impact factor: 3.590

6.  Parkinson's Disease and Its Management: Part 3: Nondopaminergic and Nonpharmacological Treatment Options.

Authors:  George DeMaagd; Ashok Philip
Journal:  P T       Date:  2015-10

Review 7.  Insights into Neuroinflammation in Parkinson's Disease: From Biomarkers to Anti-Inflammatory Based Therapies.

Authors:  Natália Pessoa Rocha; Aline Silva de Miranda; Antônio Lúcio Teixeira
Journal:  Biomed Res Int       Date:  2015-07-29       Impact factor: 3.411

Review 8.  Neuroinflammation in Parkinson's disease and its potential as therapeutic target.

Authors:  Qinqin Wang; Yingjun Liu; Jiawei Zhou
Journal:  Transl Neurodegener       Date:  2015-10-12       Impact factor: 8.014

9.  8-OH-DPAT (5-HT1A agonist) Attenuates 6-Hydroxy- dopamine-induced catalepsy and Modulates Inflammatory Cytokines in Rats.

Authors:  Hamdolah Sharifi; Alireza Mohajjel Nayebi; Safar Farajnia
Journal:  Iran J Basic Med Sci       Date:  2013-12       Impact factor: 2.699

10.  Rotenone directly induces BV2 cell activation via the p38 MAPK pathway.

Authors:  Feng Gao; Dong Chen; Qingsong Hu; Guanghui Wang
Journal:  PLoS One       Date:  2013-08-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.